Company profile: Compass Therapeutics
1.1 - Company Overview
Company description
- Provider of immune system–targeting therapeutics and antibody engineering platforms. Pipeline: CTX-009, a DLL4/VEGF-A bispecific showing benefit in colorectal and gastric cancers; CTX-471, a CD137 agonist for melanoma with U.S. studies planned H2 2024; and CTX-8371, a PD-1/PD-L1 bispecific in preclinical development for solid tumors. Platforms: StitchMabs for bispecifics, common light chain discovery, and human display for antibody tuning.
Products and services
- CTX-009: A clinical-stage bispecific antibody targeting DLL4 and VEGF-A, showing clinical benefit in advanced colorectal and gastric cancers via dual-target engagement
- StitchMabs™: A customized-format platform that links monoclonal antibodies to build bispecific antibodies, enabling tailored architectures for dual targeting through component stitching
- CTX-471: A monotherapy CD137 agonist for melanoma, aiming to initiate studies in the U.S. in H2 2024 under Compass Therapeutics’ clinical program
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Compass Therapeutics
PT Theragnostic
HQ: The Netherlands
Website
- Description: Provider of genomics-based personalized analysis for radiation sensitivity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PT Theragnostic company profile →
OncoResponse
HQ: United States
Website
- Description: Provider of immuno-oncology therapies leveraging human immune responses, with a proprietary human-antibody discovery platform sourcing antibodies from elite responder patients; OR2805 targeting M2-like tumor-associated macrophages; collaboration with MD Anderson; and a preclinical pipeline of monoclonal antibodies addressing immunosuppression in the tumor microenvironment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OncoResponse company profile →
Bolt Biotherapeutics
HQ: United States
Website
- Description: Provider of a biotechnology platform for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bolt Biotherapeutics company profile →
Sorrento Therapeutics
HQ: United States
Website
- Description: Provider of proprietary drug therapeutics under development to address unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sorrento Therapeutics company profile →
Gennao Bio
HQ: United States
Website
- Description: Provider of genetic medicines developing targeted nucleic acid therapeutics for muscle diseases, featuring GMAB, a non-viral, cell-penetrating antibody technology that delivers nucleic acid payloads into cells targeting cancer and skeletal muscle disorders, and GMAB ADC for solid tumors, an antibody-drug conjugate demonstrated in preclinical studies to deliver cytotoxic drugs directly to tumor cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gennao Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Compass Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Compass Therapeutics
2.2 - Growth funds investing in similar companies to Compass Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Compass Therapeutics
4.2 - Public trading comparable groups for Compass Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →